{"entity":{"id":"nct02952885","kind":"trial","name":"Strict IGF-1 Control in Acromegaly","aka":[],"tldr":"A phase 3 trial of Pegvisomant in Pituitary tumours, run by Unity Health Toronto, completed.","summary":"Strict IGF-1 Control in Acromegaly is a phase 3 interventional study registered as NCT02952885 by Unity Health Toronto, with 10 participants recorded, started 2017-07-27 and reaching its primary completion in 2020-05-07. Interventions recorded: Pegvisomant. Conditions recorded: Acromegaly.\n\nLinked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02952885","url":"https://clinicaltrials.gov/study/NCT02952885"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["pegvisomant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02952885","phase":"3","setting":"Strict IGF-1 Control in Acromegaly (I-Con Study)","sponsor":"Unity Health Toronto","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02952885/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/"}]}}